Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
The University of Texas MD Anderson Cancer Center · National Cancer Center Hospital East · +18 more institutions
Abstract
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC. The dual primary endpoint of progression-free survival is event driven; data were not mature at data cutoff. BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds…
Citation impact
- FWCI
- 73.81
- Percentile
- 100%
- References
- 42
Authors
15- SKScott KopetzCorresponding
The University of Texas MD Anderson Cancer Center
- TYTakayuki Yoshino
National Cancer Center Hospital East
- EVEric Van Cutsem
Universitair Ziekenhuis Leuven, KU Leuven
- CECathy Eng
Vanderbilt University, Vanderbilt-Ingram Cancer Center
- TWTae Won Kim
Ulsan College, Asan Medical Center, University of Ulsan
Topics & keywords
- Medicine
- Hazard ratio
- Cetuximab
- Clinical endpoint
- Internal medicine
- Oncology
- Colorectal cancer
- Confidence interval
- Clean water and sanitation